Mirum Pharmaceuticals (MIRM) CMO receives new equity awards

Rhea-AI Filing Summary

Mirum Pharmaceuticals reported new equity awards for its Chief Medical Officer, Joanne Quan, dated January 28, 2026. She received a stock option for 18,140 shares at an exercise price of $100.85 per share. One quarter of this option vests one year after January 28, 2026, with the remaining shares vesting in 36 equal monthly installments.

Quan was also granted 11,760 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest in three equal annual installments on each anniversary of January 28, 2026. In addition, 20,000 performance restricted stock units (PSUs) granted on January 23, 2024, had their performance criteria determined to be met on January 28, 2026. Two thirds of the PSU shares will vest on March 15, 2026 and the remaining one third on March 15, 2027.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quan Joanne

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$100.85	01/28/2026		A		18,140		(1)	01/27/2036	Common Stock	18,140	$0	18,140	D
Restricted Stock Units	(2)	01/28/2026		A		11,760		(3)	(3)	Common Stock	11,760	$0	11,760	D
Performance Restricted Stock Units	(2)	01/28/2026		A		20,000		(4)	(4)	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. 1/4th of the shares vest one year after January 28, 2026 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

3. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 28, 2026 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

4. On January 23, 2024, the reporting person was granted performance restricted stock units ("PSUs") which vest upon satisfaction of certain performance criteria. On January 28, 2026, performance criteria were determined to have been met. The shares subject to the PSUs vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.

	/s/ Judit Ryvkin, Attorney-in-Fact	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Mirum Pharmaceuticals (MIRM) report for January 28, 2026?

Mirum Pharmaceuticals reported equity awards to its CMO on January 28, 2026. Joanne Quan received stock options, restricted stock units, and performance-based units, all vesting over multi-year periods tied to service and previously established performance criteria.

How many stock options did Mirum Pharmaceuticals (MIRM) grant to its CMO?

The CMO received stock options for 18,140 shares at $100.85 per share. One quarter vests one year after January 28, 2026, with the remaining options vesting in 36 equal monthly installments thereafter, creating a long-term incentive structure.

What are the vesting terms for the Mirum Pharmaceuticals (MIRM) RSUs granted to the CMO?

The CMO received 11,760 restricted stock units vesting over three years. One third of the RSUs vests on each anniversary of January 28, 2026, so the entire award becomes fully vested on the three-year anniversary of that vesting commencement date.

How do the performance restricted stock units (PSUs) at Mirum Pharmaceuticals (MIRM) vest?

20,000 PSUs vest after performance criteria determined on January 28, 2026 were met. Two thirds of these shares will vest on March 15, 2026, and the remaining one third will vest on March 15, 2027, reflecting performance-based incentives.

When were the Mirum Pharmaceuticals (MIRM) PSUs originally granted to the CMO?

The performance restricted stock units were originally granted on January 23, 2024. These PSUs vest only after specific performance criteria were satisfied, which was confirmed on January 28, 2026, then follow scheduled vesting dates in 2026 and 2027.

Does each Mirum Pharmaceuticals (MIRM) RSU equal one share of common stock?

Each restricted stock unit represents a right to receive one share of common stock. This means the 11,760 RSUs and 20,000 PSUs correspond to the same number of underlying Mirum Pharmaceuticals common shares upon vesting and settlement.